ArticleInternational journal of biochemistry and molecular biology2022
Concurrent monkeypox and COVID-19: role of interleukin-1 receptor antagonist-like protein mechanism.
Article in International journal of biochemistry and molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn 2022, monkeypox becomes a new global public health threat. Monkeypox has been present in Africa for a very long time. The COVID-19 epidemic has been affecting this region for some years. The outbreak state persists. The coexistence of the two diseases is an intriguing discovery. There is no documentation of the co-occurrence.
methodsThe possibility of coexisting of the two lethal illnesses, monkeypox and COVID-19, is an intriguing scientific subject. Using bioinformatic pathophysiological pathway analysis, the authors investigated the pathophysiological pathways of COVID-19 and monkeypox.
resultsThe most common pathway was identified. An interleukin-1 receptor antagonist-like protein has been identified as a common pathway between the pathogenic processes of monkeypox and COVID-19.
conclusionThe findings could explain why severe COVID-19 and monkeypox do not coexist.
Indexed as
Identifiers
36419967PMC9678746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.